abstract: OBJECTIVE: To retrospectively evaluate the technical feasibility and midterm results of uncovered thoracoabdominal stent placement in complicated acute @entity1580 Stanford type B (cAADB). @entity1 AND METHODS: Fourteen consecutive @entity1 (3 females; range, 44-71 years) with cAADB who had symptomatic @entity344 and claudication underwent immediate uncovered stent implantation (diameter, 7-28 mm; length, 40-100 mm) into the true lumen of the thoracoabdominal aorta (n = 23) and visceral arteries (n = 5). RESULTS: Stenting resulted in elimination of @entity344 and symptoms in 13 of 14 @entity1 ; persisting symptoms led to secondary surgical revascularization in only 1 @entity1 . More than 1 stent ( <= 4) was placed in 7 @entity1 (2 celiac, 1 mesenteric, 2 renal, 8 aorto-iliac). Follow-up computed tomographic angiography (CTA) revealed collapse of 4 aortic stents (diameter, 9-25 mm; length, 100 mm) at 1 week in the absence of symptoms. Balloon reexpansion was possible in all 4 stents, but recollapse occurred within 1 month. Despite stent collapse, the @entity1 remained asymptomatic; ultrasonography and CTA documented sufficient perfusion of the visceral arteries in all @entity1 . Follow-up ranged from 6 months to 5 years (average, 2.5 years). Except for the @entity1 who underwent iliacomesenteric bypass for unspecific @entity490 , no other @entity1 required additional interventional or surgical therapy. CONCLUSIONS: Acute @entity1580 with suspicion of @entity63 should prompt for immediate intervention. Thoracoabdominal uncovered stent implantation is a technically feasible and effective minimally invasive approach that provided successful relief of acute @entity63 and claudication in cAADB. Stent size should be less than the normal aortic diameter to avoid possible stent collapse.

title: Uncovered stent implantation in complicated acute XXXX type B.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['visceral ischemia']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal malperfusion', 'gastrointestinal ischemia']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity1580 :: ('MESH:C562834', 'Disease') :: ['aortic dissection']

answer: @entity1580 :: (MESH:C562834,Disease) :: ['aortic dissection']


abstract: BACKGROUND: Hyperbaric @entity26 (HBO) has been proven to enhance bone and soft tissue healing in @entity63 tissue in vitro and in vivo studies. Although only a few reports have been proven using controlled studies, this treatment modality remains encouraging for @entity6275 . In this retrospective study, we reported the clinical results of HBO therapy for @entity6275 . METHODS: From January through August 2000, 14 @entity1 with @entity6275 treated with HBO were available for follow-up examination. According to the Cierny-Mader classification, all @entity1 were classified as type III or IV @entity4034 . Adequate debridement and parenteral antibiotic treatment in conjunction with HBO therapy at 2.5 atmospheres absolute for 120 minutes, and 5 days per week regimen was used in all @entity1 . The @entity1 were followed-up for an average of 15 months after completion of HBO therapy. RESULTS: The most common infecting microorganism was @entity794 . Mixed @entity281 were usually found in @entity1 with @entity4422 . The average number of operations before HBO therapy was 5.4 including soft tissue reconstruction in 11 @entity1 . The average number of HBO treatments was 33.6 times. There were no HBO related complications. No recurrence of @entity281 was noted in 11 @entity1 , which resulted in a success rate of 79%. CONCLUSIONS: Hyperbaric @entity26 therapy is effective and safe for @entity6275 provided that @entity1 had received appropriate medical and surgical management.

title: Hyperbaric @entity26 therapy in the treatment of XXXX : a preliminary report.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6275 :: ('MESH:C535456', 'Disease') :: ['chronic refractory osteomyelitis', 'chronic refractory osteomyelitis of the tibias']

entities_list: @entity4422 :: ('MESH:D005597', 'Disease') :: ['open fractures']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity4034 :: ('MESH:D010019', 'Disease') :: ['osteomyelitis']

entities_list: @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'infections']

answer: @entity6275 :: (MESH:C535456,Disease) :: ['chronic refractory osteomyelitis']


abstract: The air crescent sign is regarded as an important diagnostic finding in invasive @entity57 (IPA). This study examined the incidence, clinical importance, and natural history of air crescents in 25 @entity1 with @entity3052 and IPA. Twelve (50%) of the @entity1 had cavities (ten with an air crescent) that appeared an average of 15 days after the initial infiltrate. The diagnostic utility of the air crescent sign was relatively minor; cavities developed after the diagnosis was established in 50% of cases and after therapy was started in 75% of cases. In each case, the @entity55 improved at the time of cavitation. In six @entity1 (50%), the cavities resolved over 2-8 months. Three @entity1 (25%), however, experienced massive hemoptysis. Air crescent formation, previously shown to be dependent on granulocyte recovery, was associated with improved survival (67%) compared with the group without cavitation (8%). In the latter group, the @entity55 in ten (77%) of 13 @entity1 progressed to diffuse disease. In @entity1 with @entity1778 , the diagnostic value of the air crescent sign is limited by cavities that develop relatively late, as the infection improves after white blood cell recovery; cavities that do not occur in @entity1 who remain @entity1398 ; and associated @entity548 , at times life-threatening, that obscures the air crescent. The diagnosis of IPA should not await observation of air crescents in these @entity1 .

title: Invasive XXXX and @entity3052 . Limitations in the diagnostic utility of the air crescent sign.

entities_list: @entity57 :: ('MESH:D055732', 'Disease') :: ['pulmonary aspergillosis']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute leukemia']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenic']

answer: @entity57 :: (MESH:D055732,Disease) :: ['pulmonary aspergillosis']


abstract: BACKGROUND: Treatment guidelines for typical @entity5 recommend observation alone after resection of stage I-IIIA disease, but there are limited data related to the use of adjuvant chemotherapy in the setting of nodal metastases found at operation. METHODS: @entity1 in the National Cancer Data Base (NDCB) who underwent lobectomy for typical @entity4303 and had metastatic nodal disease were stratified by the use of adjuvant chemotherapy. Baseline characteristics and outcomes were compared between groups. Next, @entity1 were propensity matched using a 3:1 nearest-neighbor algorithm, and adjusted outcomes were compared. Finally, long-term survival was evaluated using the Kaplan-Meier method with comparisons based on the log-rank test. RESULTS: Overall, 4,612 @entity1 were identified, among whom 629 (13.6%) had positive lymph nodes at the time of operation. Of them, adjuvant chemotherapy was used in 37 @entity1 (5.9%). There were no baseline differences between @entity1 who did and those who did not receive adjuvant chemotherapy. @entity1 treated with chemotherapy demonstrated a survival disadvantage at 5 years (69.7% versus 81.9%; p  = 0.042). After propensity matching, all baseline characteristics between groups were highly similar. There remained a trend toward inferior 5-year survival for @entity1 who received adjuvant chemotherapy, although the difference no longer met statistical significance (69.7% versus 80.9%; p  =  0.096). CONCLUSIONS: Adjuvant chemotherapy is not associated with improved survival among @entity1 who undergo lobectomy for @entity4303 and nodal metastases. These data support current treatment guidelines.

title: Defining the Role of Adjuvant Chemotherapy After Lobectomy for Typical XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['bronchopulmonary carcinoid tumors']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity4303 :: ('MESH:D002276', 'Disease') :: ['typical carcinoids', 'carcinoid']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Bronchopulmonary Carcinoid Tumors']


abstract: OBJECTIVE: To examine socioeconomic differences in case fatality and prognosis of @entity583 ( @entity583 ) events, and to estimate the contributions of incidence and case fatality to socioeconomic differences in @entity301 ( @entity301 ) mortality. DESIGN: A population-based @entity583 register study. METHODS: The FINMONICA @entity583 Register recorded all @entity583 events among @entity1 aged 35-64 years in three areas of Finland during 1983-1992. A record linkage of the @entity583 Register data with the files of Statistics Finland was performed to obtain information on socioeconomic indicators for each individual registered. First @entity583 events (n=8427) were included in the analyses. MAIN RESULTS: The adjusted risk ratio of prehospital coronary @entity204 was 2.11 (95% CI 1.82, 2.46) among @entity1 and 1.68 (1.14, 2.48) among @entity1 with low income compared with those with high income. Even among @entity1 hospitalised alive the risk of @entity204 during the next 12 months was markedly higher in the low income group than in the high income group. Case fatality explained 51% of the @entity301 mortality difference between the low and the high income groups among @entity1 and 38% among @entity1 . Incidence contributed 49% and 62%, respectively. CONCLUSIONS: Considerable socioeconomic differences were observed in the case fatality of first coronary events both before hospitalisation and among @entity1 hospitalised alive. Case fatality explained a half of the @entity301 mortality difference between the low and the high income groups among @entity1 and more than a third among @entity1 .

title: Relation of socioeconomic position to the case fatality, prognosis and treatment of XXXX events; the FINMONICA @entity583 Register Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'persons', 'men']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['CHD', 'coronary heart disease']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']


abstract: More @entity1 are now being diagnosed with nonpalpable @entity263 after a needle biopsy is performed for an elevated prostate-specific antigen (PSA) level (stage T1c). The purpose of this study was to identify prognostic factors that are associated with biochemical failure after definitive external beam radiation therapy. This study included 75 @entity1 with the diagnosis of @entity263 who were referred to four radiation oncology centers in the West Chicago area from 1992 to 1995. All @entity1 were treated with megavoltage external beam radiotherapy to doses between 66 and 70 Gy. Biochemical failure was defined as three consecutive rising PSA values of at least 10% of the prior reading in posttreatment serial measurements. The mean age of the @entity1 was 72 years. The mean follow-up was 1.7 years (range, 1-3 1/2 years). Of the 75 @entity1 , 72 (96%) are clinically with no evidence of disease, three of the 75 are alive with disease, and 60 (80%) remain biochemically free of disease (bNED). The significant factors for bNED status were an initial PSA level of <15 ng/ml (p = 0.0001), achievement of a posttreatment nadir PSA level of < or = 1.5 ng/ml (p = 0.0001), and a Gleason score of <6 (p = 0.034). Multisextant involvement with @entity5 or bilobar disease was not significant. On multivariate analysis, an initial PSA level of <15 ng/ml (p = 0.0001), Gleason score of <6 (p = 0.02), and nadir PSA level of < or = 1.5 ng/ml (p = 0.03) were significant predictors of bNED survival. @entity1 with @entity263 comprise a heterogeneous group. @entity1 with a high PSA level (>15 ng/ml) and high Gleason score (>6) are at increased risk for biochemical failure. Failure to achieve a posttreatment nadir PSA level of < or = 1.5 ng/ml is a predictor of ultimate biochemical failure.

title: Factors that influence biochemical failure after radiation therapy for stage XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Men']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['T1c prostate cancer', 'prostate cancer']

answer: @entity263 :: (MESH:D011471,Disease) :: ['T1c prostate cancer']


abstract: OBJECTIVES/HYPOTHESIS: In order to make possible organ preservation, since 2007 our hospital has performed @entity7730 ( @entity7730 ) with @entity900 and @entity1487 (PF) for @entity5 as chemoselection, followed by alternating chemoradiotherapy (ACRT) with @entity1205 , @entity900 , and @entity1487 in (TPF) good responders and curative surgery was used in poor responders. METHODS: Twenty-six @entity1 with stage III to stage IVB @entity5 received @entity7730 . Eleven of the @entity1 were classified as poor responders and received curative surgery. The remaining 15 @entity1 were classified as good responders. Three of these @entity1 underwent curative surgery, and the remaining 12 underwent ACRT. RESULTS: The primary lesions in the 12 ACRT @entity1 responded completely to treatment without severe late @entity137 . The estimated 3-year laryngectomy-free rate for all 26 @entity1 was 23%. The estimated 3-year overall survival rates for all 26 @entity1 , 12 @entity1 treated with ACRT, and 14 @entity1 who underwent curative surgery, were 79%, 75%, and 84%, respectively. CONCLUSION: The @entity1 who underwent ACRT showed no significant difference in overall survival compared with the @entity1 who underwent curative surgery. All the @entity1 were able to proceed with this series of therapy, indicating that @entity7730 with PF could be a feasible tool for choosing good responders. Because ACRT with TPF had a high response rate and fewer severe @entity137 , this treatment could be safe and have enough impact to control @entity5 in good responders. LEVEL OF EVIDENCE: 4. Laryngoscope, 2015.

title: Chemoselection combined with alternating chemoradiotherapy or surgery for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['hypopharyngeal cancer']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity7730 :: ('MESH:D064146', 'Disease') :: ['ICT', 'induction chemotherapy']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']

answer: @entity5 :: (MESH:D009369,Disease) :: ['hypopharyngeal cancer']


abstract: BACKGROUND: The cognitive fusion questionnaire (CFQ) is a self-report questionnaire that assesses the extent to which individuals are psychologically entangled with, and dominated by the form-content of their thoughts. The aim of this study was to replicate the factor structure of CFQ in @entity66 , @entity6 , @entity28 , @entity308 , and normative population. It further examined the factorial invariance of the CFQ across these 5 groups. METHOD: Data from 299 @entity1 (N General Population   =  67, N @entity66   =  73, N @entity6   =  47, N @entity308   =  45, and N Obesity   =  60) were subjected to confirmatory factorial analysis ( @entity3795 ) to replicate the structural model of CFQ dimensionality. RESULTS: @entity3795 supported a 1-factor structure with good internal consistency and construct related validity. The 1-factor solution was also supported by a second independent data set, which showed a configural, strict measurement, and structural invariance of the 1-factor solution proposed. Multigroup @entity3795 showed the configural invariance, strict measurement invariance, and structural invariance of CFQ across the 5 groups under study. CONCLUSIONS: The unidimensional model has both similar meanings and the same structure, but the measurement model across the groups was not the same. The study provides the first approach to CFQ to Portuguese population, as a reliable tool of general cognitive fusion. Furthermore, results indicated that CFQ has a coherent structure across multiple samples and clinical utility, as it discriminate individuals with @entity458 from those who do not.

title: Validation of the psychometric properties of cognitive fusion questionnaire. A study of the factorial validity and factorial invariance of the measure among @entity66 , @entity6 , XXXX , @entity308 , and general populations.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depressive Disorder', 'depressive disorder']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Osteoarticular Disease', 'osteoarticular disease']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes Mellitus', 'diabetes mellitus']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['psychological distress']

answer: @entity28 :: (MESH:D009765,Disease) :: ['obesity']


abstract: The @entity649 ( @entity649 ) frequently results in a fibroproliferative response that precludes effective alveolar repair. @entity310 ( @entity7790 ), a potent epithelial and mesenchymal cell mitogen, may modulate the response to @entity651 . In this study, we determined whether bronchoalveolar lavage fluid (BALF) concentrations of @entity7790 are increased during the first 2 wk after the onset of @entity649 and, if so, whether increased @entity7790 levels in lavage fluid are associated with increased levels of procollagen peptide III (PCP III), a biological marker of fibroproliferation, and with increased fatality rates. We enrolled 74 consecutive @entity1 with @entity649 prospectively identified on admission to the intensive care unit of a tertiary care hospital, and 11 @entity1 with chronic @entity401 . Thirteen healthy volunteers served as control subjects. @entity7790 concentrations were measured in BALF recovered on Days 3, 7, and 14 after the onset of @entity649 (total of 130 lavage samples). @entity7790 was detected in the lavage fluid of 90% of @entity1 with @entity649 (67 of 74), and in 100% of @entity1 with @entity2416 ( @entity2416 ) (10 of 10), but in none of 13 normal volunteers. At each day tested, the median lavage @entity7790 level of @entity1 with @entity649 was significantly higher than that of normals. The overall fatality rate was 45% (33 of 74 @entity1 ). In a univariate analysis, the median @entity7790 levels in nonsurvivors were 1.5-fold higher at Day 7 (p = 0.06) and 1.8-fold higher at Day 14 (p = 0.048). The fatality rate was 4 times higher (CI 1.6, 17.5) for @entity1 with both increased lavage @entity7790 and PCP III concentrations at Day 7 than for @entity1 with low @entity7790 and PCP III values, indicating a synergistic relationship between @entity7790 and PCP III. We conclude that increased levels of @entity7790 in BALF are common in @entity1 with @entity649 and that lavage @entity7790 is associated with a marker of the fibroproliferative response in sustained @entity649 .

title: Elevated XXXX levels in bronchoalveolar lavage fluid of @entity1 with @entity649 .

entities_list: @entity310 :: ('7124', 'Gene') :: ['Transforming growth factor-alpha']

entities_list: @entity649 :: ('MESH:D012128', 'Disease') :: ['ARDS', 'acute respiratory distress syndrome']

entities_list: @entity651 :: ('MESH:D055370', 'Disease') :: ['lung injury']

entities_list: @entity2416 :: ('MESH:D054990', 'Disease') :: ['IPF', 'idiopathic pulmonary fibrosis']

entities_list: @entity401 :: ('MESH:D017563', 'Disease') :: ['interstitial lung disease']

answer: @entity310 :: (7124,Gene) :: ['transforming growth factor-alpha']


abstract: BACKGROUND: The purpose of this study was to examine the effects of intravenous @entity6948 on the duration of @entity1341 -induced epidural anaesthesia and level of wakefulness and the respective side-effects. METHODS: Sixty ASA I-II @entity1 were included in the study. Consecutive @entity1 were allocated to groups according to the last digit (odd/even) of their admission numbers. All @entity1 had epidural anaesthesia with @entity1341 0.5% performed by the same experienced anaesthesiologist. In the first group, the @entity1 were administered intravenous @entity6948 infusion just after the epidural block and continued during the operation, while those in the second group were administered physiologic saline infusion at the same amount and duration. RESULTS: The recovery time of sensory block was significantly longer in the first group. The bispectral index values were lower in the first group than in the second. Also, heart rate was significantly lower in Group I than in Group II. Regarding side-effects, shivering was significantly less frequent in the first group, whereas there was a significant increase in the requirement of @entity3897 in the first group as @entity6948 caused @entity1168 . CONCLUSION: Intravenous administration of @entity6948 prolonged the duration of epidural anaesthesia, provided sedation and had few side-effects.

title: Effects of @entity6948 on the duration of anaesthesia and wakefulness in XXXX epidural block.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1341 :: ('MESH:D002045', 'Chemical') :: ['bupivacaine']

entities_list: @entity3897 :: ('MESH:D001285', 'Chemical') :: ['atropine']

entities_list: @entity6948 :: ('MESH:D020927', 'Chemical') :: ['dexmedetomidine']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']

answer: @entity1341 :: (MESH:D002045,Chemical) :: ['bupivacaine']


abstract: UNASSIGNED: A 44-year-old male with no pertinent history other than poor vision for more than 25 years was examined. Best corrected visual acuity was 20/80 OD [MR: +14.25 +1.00   *   15  ] and 20/200 OS [MR: +15.00 +1.50   *   175  ]. Significant limitation in ocular movements and the presence of an orbital lipodermoid in the infero-temporal aspect of each eye were noted. Forced duction test was positive for the same directions of limitation indicating possible extraocular muscle @entity82 . Ophthalmoscopy was remarkable for the presence of peripheral bony spicules. Corneal topography was compatible with @entity9042 (Kmax   =   55.04D OD and 52.87D OS). A-scan revealed axial lengths of 16.96   mm OD and 16.32   mm OS, compatible with a diagnosis of @entity4355 . @entity6653 revealed diffuse macular thickening for both eyes with foveal thickness of 350     m OD and 353     m OS. Over the next 12 years the @entity1 had stable visual acuity, manifest refractions and anterior segment examination. Ophthalmoscopy revealed only minimal progression of pigmentary changes. We report the first case of these simultaneous multiple findings which may refer to a possible syndromic association of congenital or early childhood onset.

title: A @entity1 with XXXX , Nanophthalmos, Lipodermoids, and Pigmentary Retinopathy.

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity9042 :: ('MESH:D007640', 'Disease') :: ['keratoconus']

entities_list: @entity4355 :: ('MESH:C563983', 'Disease') :: ['nanophthalmos']

answer: @entity9042 :: (MESH:D007640,Disease) :: ['Keratoconus']


abstract: OBJECTIVE: The objective of this study was to determine the efficacy of percutaneous radiofrequency (RF) thermocoagulation of the ramus communicans nerve in @entity1 suffering from @entity1643 . METHODS: Forty-nine @entity1 who suffered @entity1643 at only 1 painful vertebral level, and whose @entity158 continued after undergoing intradiscal electrothermal annuloplasty (IDET), were randomly assigned to 1 of 2 treatment groups. The lesion group (n = 26) received RF thermocoagulation of the ramus communicans nerve. @entity1 in the control group (n = 23) received an injection of @entity3303 without radiofrequency. Visual analog scale (VAS) @entity158 scores, analgesic requirements, SF-36 subscales, and the overall @entity1 satisfaction with the procedure were tabulated. RESULTS: The average follow-up period was 4 months. The @entity1 -reported VAS @entity158 scores were significantly lower (P < 0.05) in the lesion group. The scores of the RF lesion group improved by a mean increase of 11.3 points (P < 0.05) on the SF-36 bodily @entity158 subscale, and by a mean increase of 12.4 points on the physical function subscale (P < 0.05). In a follow-up analysis within the RF lesion group, VAS @entity158 scores improved by a mean reduction of 3.32 (P = 0.001). The scores improved by a mean increase of 14.5 points (P = 0.005) on the SF-36 bodily @entity158 subscale and 15.2 points(P = 0.002) on the physical function subscale within the RF lesion group. One @entity1 in the lesion group complained of mild @entity425 , but he completely recovered at postoperative 15 days without any serious problems. DISCUSSION: In @entity1 with @entity1643 , percutaneous RF denervation of the ramus communicans nerve should be considered as a treatment option.

title: A randomized controlled trial of radiofrequency denervation of the ramus communicans nerve for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity1643 :: ('MESH:D017116', 'Disease') :: ['chronic discogenic low back pain']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['lower limb weakness']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine']

answer: @entity1643 :: (MESH:D017116,Disease) :: ['chronic discogenic low back pain']


abstract: AIM: To study the frequency of borderline @entity146 in @entity1 of secondary general education schools. MATERIAL AND METHODS: We examined 1013 male and female schoolchildren, aged 12-14 and 15-17 years. In the first stage, the they completed a screening questionnaire to estimate the presence of a range of @entity5539 . An analysis of medical history and clinical examination were performed as well. The second stage included medical examination using DAWBA for the @entity1 with total scores on The Strengths and Difficulty questionnaire >= 16; with the score >= 6 on the emotional scale and with the score  <=5 on the social scale. RESULTS AND CONCLUSION: Generalized anxiety and @entity308 were recorded more often in @entity1 than in @entity1 . Every 4-th adolescent (26.1%), regardless of gender, had problems in communication with peers. At the same time, @entity1 showed conduct disturbances more often (p=0.005) than @entity1 (23.3% and 16.3%, respectively). @entity308 was 6,1 times more frequent in adolescents of the older group as compared with younger @entity1 (  =0.024). @entity308 was associated with @entity2794 (68.6% of @entity1 , mostly in @entity1 and in the older group), @entity490 (37.3%, mostly in @entity1 ) and back pain (39.2%).

title: [Borderline XXXX in schoolchildren].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'girls', 'boys']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depression', 'Depression syndrome']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['mental disorders']

entities_list: @entity5539 :: ('MESH:D011602', 'Disease') :: ['psychosomatic syndromes']

entities_list: @entity2794 :: ('MESH:D020773', 'Disease') :: ['chronic headache']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

answer: @entity146 :: (MESH:D001523,Disease) :: ['mental disorders']


abstract: UNASSIGNED: The combination of @entity3601 , @entity229 and @entity2816 (MPT) is considered standard therapy for newly diagnosed @entity1 with @entity1582 (NDMM) who are ineligible for stem-cell transplantation. Long term treatment with @entity2816 is hampered by @entity2359 . @entity3601 , @entity229 and @entity6985 , followed by @entity6985 maintenance therapy showed promising results, without severe @entity16 emerging. We randomly assigned 668 NDMM @entity1 , ineligible for stem-cell transplantation, between nine 4-weekly cycles of MPT followed by @entity2816 maintenance until disease progression or unacceptable @entity137 ( @entity1619 ) and the same MP regimen with @entity2816 being replaced by @entity6985 (MPR-R). This multicenter, open-label, randomised phase 3 trial was undertaken by HOVON and the NMSG. The primary endpoint was progression-free survival (PFS). The accrual for the study was completed in October 19, 2012. 318 @entity1 were randomly assigned to receive @entity1619 and 319 MPR-R. After a median follow up of 36 months PFS with @entity1619 was 20 months (95% CI 18-23 months) versus 23 months (95% CI 19-27 months) with MPR-R (HR 0.87 [0.72-1.04], p=0.12). Response rates were similar, with >= VGPR 47% and 45% respectively. @entity1503 was more pronounced with MPR-R, especially grade 3 and 4 @entity1398 : 64 versus 27%. Neuropathy >=  grade 3 was significantly higher in the @entity1619 arm; 16% versus 2% in MPR-R, resulting in a significant shorter duration of maintenance therapy (5 versus 17 months in MPR-R), irrespective of age. MPR-R has no advantage over @entity1619 concerning efficacy. The @entity137 profile differed with clinically significant @entity16 during @entity2816 maintenance versus myelosuppression with MPR.

title: @entity6985 plus @entity3601 and @entity229 , followed by @entity6985 maintenance versus XXXX plus @entity3601 and @entity229 , followed by @entity2816 maintenance; results of the randomised phase 3 HOVON 87/NMSG18 trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy']

entities_list: @entity2816 :: ('MESH:D013792', 'Chemical') :: ['thalidomide']

entities_list: @entity3601 :: ('MESH:D008558', 'Chemical') :: ['melphalan', 'Melphalan']

entities_list: @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['Hematological toxicity']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity6985 :: ('MESH:C467567', 'Chemical') :: ['lenalidomide']

entities_list: @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity']

answer: @entity2816 :: (MESH:D013792,Chemical) :: ['thalidomide']


abstract: PURPOSE: To outline the clinical characteristics of @entity410 in our large series of @entity66 ( @entity66 ) @entity1 with neurologic involvement. METHODS: All files of 223 @entity1 with neuro- @entity66 were evaluated retrospectively, and the group with clearly documented @entity410 was included in the current study. Clinical characteristics, EEG, neuroimaging and cerebrospinal fluid findings were reevaluated, and the @entity410 were classified according to the new proposed criteria of the International League Against @entity302 . On excluding the @entity1 in whom the @entity410 were due to possible @entity410 -provoking factors, the @entity410 that appeared during a neurologic exacerbation were noted. RESULTS: @entity410 were seen in 10 (4.48%) of 223 @entity1 . There were one female and nine male @entity1 . In five of the @entity1 , @entity410 occurred during neurologic exacerbation. Therefore, the actual prevalence of @entity410 due to @entity66 in our group is 2.2%. In the remaining five @entity1 , the @entity410 were not related to @entity16 attacks, but probably were due to some @entity410 -provoking factors. The predominating @entity410 type was generalized tonic-clonic @entity410 accompanied by @entity410 . It is notable that four @entity1 died 1-5 years after the onset of the @entity410 . CONCLUSIONS: Our study showed that @entity410 are rare in @entity66 . As the @entity410 due to some interventions and drugs are as frequent as neuro- @entity66 -related @entity410 , @entity410 -provoking factors must be considered before attributing them to the pathogenetic mechanism of @entity66 . The occurrence of @entity410 seems to be associated with a high mortality rate.

title: @entity302 in XXXX .

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'Seizures', 'seizures', 'convulsions', 'focal motor seizures']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Beh  et disease', 'BD']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurologic BD']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['Epilepsy']

answer: @entity66 :: (MESH:D004194,Disease) :: ['Beh  et disease']


abstract: OBJECTIVE: A phase II study was conducted to determine the efficacy of @entity901 therapy in @entity1 with previously treated @entity957 . METHODS: Eligible @entity1 were to have measurable disease and not more than one prior chemotherapy regimen that could include @entity3003 or @entity900 but not @entity901 . @entity901 130 mg/m(2) was administered intravenously over 2 h. This treatment was repeated every 21 days until progression of disease or adverse effects prohibited further therapy. RESULTS: Twenty-eight @entity1 were entered onto this study, of whom 24 were evaluable for @entity137 and 22 were evaluable for response; 23/24 evaluable @entity1 had had prior @entity902 . There were two (8.3%) responses. One @entity1 achieved a complete response which lasted 2.2 months, and a second @entity1 attained a partial response which lasted 3.2 months. Nine (37.5%) @entity1 had stable disease with a median duration of 7.6+ (3.1-21.2) months. The most frequently reported drug-related @entity137 consisted of @entity417 , @entity390 and @entity391 , and @entity2359 . Three (12.5%) @entity1 had a grade 3 @entity56 response that was infusion-related and was largely resolved by increasing infusion time. CONCLUSIONS: @entity901 has limited activity in @entity1 with persistent or recurrent @entity957 at the dose and schedule tested.

title: Phase II evaluation of @entity901 in previously treated XXXX : a gynecologic oncology group study.

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin', 'Oxaliplatin']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma of the cervix']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

answer: @entity957 :: (MESH:D002294,Disease) :: ['squamous cell carcinoma of the cervix']


abstract: OBJECTIVE: This study was undertaken to examine both isolated and concomitant @entity99 to clarify the role of liver @entity130 on outcome. @entity1 AND METHODS: This retrospective study was a review of all @entity1661 @entity1 who presented with @entity99 , with or without concomitant injury at Ege University School of Medicine over a 3-year period. Presentation, injury grade, management, and outcomes were analyzed. @entity1 with isolated @entity99 (Group A) were compared with @entity1 who had concomitant @entity99 (liver and spleen/small bowel) (Group B). Significance was set at 95% confidence intervals. RESULTS: Of 368 @entity1 , 80 (21%) presented with @entity99 . Of these, the aetiology was as follows: 53 (66.2%) @entity1913 , 19 (23%) penetrating injury, and 8 (10%) gun shot @entity130 . There were 38 @entity1 in Group A and 42 in Group B. Of these 42 @entity1 , 19 were diagnosed with serious @entity130 ; eight thoracic, three open long bone @entity174 , one intra-cardiac, one intracranial. Six additional @entity1 were observed with injuries to large abdominal vessels. Eleven @entity1 (28.9%) with isolated @entity99 were managed non-operatively. Mortality, intensive care unit and hospital length of stay, and transfusion requirements were significantly higher in Group B. Only the number of transfused blood units and the grade of @entity99 were found to be effective on outcome whereas stepwise regression analysis revealed that @entity130 (penetrating) and blood transfusion were predictive for mortality. CONCLUSION: This study highlighted that although isolated @entity99 results in good outcome with non-operative management, concomitant injuries to the liver lead to a higher failure and mortality rate. However, @entity99 itself is rarely responsible for @entity204 .

title: Comparison of isolated and concomitant @entity99 : is XXXX entirely responsible for the outcome?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

entities_list: @entity1661 :: ('MESH:D000008', 'Disease') :: ['abdominal trauma']

entities_list: @entity1913 :: ('MESH:D014949', 'Disease') :: ['blunt injury']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['liver injuries', 'hepatic injury', 'liver injury']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['types of injury', 'trauma', 'injury type']

answer: @entity99 :: (MESH:D056486,Disease) :: ['hepatic trauma']


abstract: OBJECTIVES: The goal of this study was to investigate the hemodynamic and circulatory adjustments to extracorporeal ultrafiltration (UF) in refractory congestive @entity712 (rCHF). BACKGROUND: In rCHF, UF allows clinical improvement and restores diuretic efficacy. However, in the course of a UF session, @entity1 are exposed to rapid variations of body fluid composition so that, as fluid is withdrawn from the intravascular compartment, @entity551 or even shock could occur. METHODS: In 24 @entity1 with rCHF undergoing UF, we measured, after every liter of plasma water removed, hemodynamics, blood gas analysis (in both @entity358 ), plasma volume changes (PV) and plasma refilling rate (PRR). The PV and PRR were calculated by considering hematocrit and ultrafiltrate volume. RESULTS: In all @entity1 , UF was performed safely, without side effects or hemodynamic instability (ultrafiltrate = 4,880 +/- 896 ml). Mean right @entity358 and wedge pressures progressively reduced during the procedure. Cardiac output increased at the end of the procedure and, to a greater extent, 24 h later, in relation to the increase of @entity64 volume. Heart rate and systemic vascular resistance did not increase, and other peripheral biochemical parameters did not worsen during UF. Intravascular volume remained stable throughout the entire duration of the procedure, indicating that a proportional volume of fluid was refilled from the congested parenchyma. CONCLUSIONS: In @entity1 with rCHF, subtraction of plasma water by UF is associated with hemodynamic improvement. Fluid refilling from the overhydrated interstitium is the major compensatory mechanism for intravascular fluid removal, and @entity551 does not occur when plasma refilling rate is adequate to prevent @entity3485 .

title: Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['atrial, pulmonary artery', 'systemic and pulmonary arteries']

entities_list: @entity3485 :: ('MESH:D020896', 'Disease') :: ['hypovolemia']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

answer: @entity712 :: (MESH:D006333,Disease) :: ['heart failure']


abstract: UNASSIGNED: Chromosome rearrangement is clinically and physiologically important because it can produce oncogenic fusion genes. Chromosome rearrangement requires DNA double-strand breaks (DSBs) at two genomic locations and misrejoining between the DSBs. Before DSB misrejoining, two DSB-containing chromatin regions move and pair with each other; however, the molecular mechanism underlying this process is largely unknown. We performed a spatiotemporal analysis of ionizing radiation-induced foci of @entity15664 ( @entity15664 ), a marker for DSB-containing chromatin. We found that some @entity15664 foci were paired, indicating that the two damaged chromatin regions neighboured one another. We searched for factors regulating the foci pairing and found that the number of paired foci increased when @entity10321 , @entity10322 , or ATM was absent. In contrast, @entity15664 depletion reduced the number of paired foci and dicentric chromosomes-an interchromosomal rearrangement. Foci were paired more frequently in heterochromatin than in euchromatin in control cells. Additionally, the reduced foci pairing in @entity15664 -depleted cells was rescued by concomitant depletion of a heterochromatin building factor such as Kr  ppel-associated box-associated protein 1 or @entity34255 . These findings indicate that pairing between DSB-containing chromatin regions was suppressed by @entity10321 , @entity10322 , and ATM, and this pairing was promoted by @entity15664 through chromatin relaxation.

title: Regulation of pairing between broken DNA-containing chromatin regions by @entity10321 , XXXX , ATM, and 53BP1.

entities_list: @entity34255 :: ('1107', 'Gene') :: ['chromodomain helicase DNA-binding protein 3']

answer: @entity10322 :: (5591,Gene) :: ['DNA-PKcs']


abstract: UNASSIGNED: @entity1149 ( @entity1149 ) remains the most common cause of @entity5 worldwide. @entity1 presenting with advanced-stage @entity1149 have poor prognosis, while metastatic spread accounts for >70  % of @entity1 's deaths. The major advances in the treatment of @entity2 have brought only minor improvements in survival; therefore, novel strategic treatment approaches are urgently needed. Accumulating data allocate a central role for the @entity5 microenvironment including mesenchymal stem cells (MSCs) in acquisition of drug resistance and disease relapse. Furthermore, studies indicate that translation initiation factors are over expressed in @entity1149 and negatively impact its prognosis. Importantly, translation initiation is highly modulated by microenvironmental cues. Therefore, we decided to examine the effect of bone marrow MSCs (BM-MSCs) from normal donors on @entity1149 cell lines with special emphasis on translation initiation mechanism in the crosstalk. We cultured @entity1149 cell lines with BM-MSC conditioned media (i.e., secretome) and showed deleterious effects on the cells' proliferation, viability, @entity204 , and migration. We also demonstrated reduced levels of translation initiation factors implicated in @entity5 progression [ @entity4043 ( @entity4043 ) and @entity5290 ( @entity5290 )], their targets, and regulators. Finally, we outlined a mechanism by which BM-MSCs' secretome affected @entity1149 's mitogen-activated protein kinase (MAPK) signaling pathway, downregulated the cell migration, and diminished translation initiation factors' levels. Taken together, our study demonstrates that there is direct dialogue between the BM-MSCs' secretome and @entity1149 cells that manipulates translation initiation and critically affects cell fate. We suggest that therapeutic approach that will sabotage this dialogue, especially in the BM microenvironment, may diminish @entity2 metastatic spread and morbidity and improve the @entity1 's life quality.

title: Secretome of XXXX bone marrow mesenchymal stem cells: an emerging @entity2 progression and mechanisms of translation initiation.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer-related death', 'cancer']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'Non-small cell lung cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity5290 :: ('1981', 'Gene') :: ['eIF4GI', 'eukaryotic translation initiation factor 4GI']

entities_list: @entity4043 :: ('1977', 'Gene') :: ['eIF4E', 'eukaryotic translation initiation factor 4E']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVES: @entity293 caused by uropathogenic @entity526 (UPEC) strains is one of the most important infections in the world. UPEC encode widespread virulence factors closely related with pathogenesis of the bacteria. The purpose of this study was to evaluate the presence of different phenotypic virulence markers in UPEC isolates and determine their correlation with antibiotic resistance pattern. METHODS: UPEC isolates from @entity1 with different clinical symptoms of UTI were collected and screened for biofilm and hemolysin production, @entity3913 resistant, and @entity3913 sensitive hemagglutination (MRHA and MSHA, respectively). In addition, antimicrobial resistance pattern and ESBL-producing isolates were recorded. RESULTS: Of the 156 UPEC isolates, biofilm and hemolysin formation was seen in 133 (85.3%) and 53 (34%) isolates, respectively. Moreover, 98 (62.8%) and 58 (37.2%) isolates showed the presence of Types 1 fimbriae (MSHA) and P fimbriae (MRHA), respectively. Our results also showed a relationship between biofilm formation in UPEC isolated from acute @entity2335 @entity1 and recurrent UTI cases. Occurrence of UTI was dramatically correlated with the @entity1 ' profiles. We observed that the difference in antimicrobial susceptibilities of the biofilm and nonbiofilm former isolates was statistically significant. The UPEC isolates showed the highest resistance to @entity869 , @entity803 , @entity115 , and @entity799 . Moreover, 26.9% of isolates were ESBL producers. CONCLUSION: This study indicated that there is a relationship between the phenotypic virulence traits of the UPEC isolates, @entity1 ' profiles, and antibiotic resistance. Detection of the phenotypic virulence factors could help to improve understanding of pathogenesis of UPEC isolates and better medical intervention.

title: Phenotypic Assays to Determine Virulence Factors of Uropathogenic XXXX (UPEC) Isolates and their Correlation with Antibiotic Resistance Pattern.

entities_list: @entity115 :: ('MESH:D000658', 'Chemical') :: ['amoxicillin']

entities_list: @entity799 :: ('MESH:D015662', 'Chemical') :: ['cotrimoxazole']

entities_list: @entity869 :: ('MESH:D000667', 'Chemical') :: ['ampicillin']

entities_list: @entity803 :: ('MESH:D013752', 'Chemical') :: ['tetracycline']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['Urinary tract infection']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli']

answer: @entity526 :: (562,Species) :: ['Escherichia coli']


abstract: UNASSIGNED: The purpose of this study is to compare the @entity2194 and the amblyopic eyes using enhanced depth imaging optical coherence tomography (EDI-OCT) in young Turkish adults with hyperopic @entity4457 . @entity1 with unilateral hyperopic @entity4457 were enrolled and underwent a full ophthalmological assessment, including best-corrected visual acuity, cycloplegic refraction, and axial length (AL) measurements. Cirrus EDI-OCT was used to obtain subfoveal CT, GCC thickness, retinal nerve fiber layer (RNFL), and central macular thickness (CMT) measurements. Comparison was performed between the amblyopic eyes and the normal fellow eyes. Forty-three hyperopic anisometropic amblyopic @entity1 were enrolled in this study. Mean age of 23 female and 20 male @entity1 was 24.8      7.4  years. Mean AL was 21.9      1.3 and 22.4      0.9  mm in amblyopic and fellow eyes, respectively (P  <  0.05). Mean subfoveal CT measurements were 325.4      44.2 and 317.9      42.7     in amblyopic and fellow eyes, respectively. There was no statistically significant difference between the groups (P  >  0.05). Mean GCC thickness was 83.8      3.6     in amblyopic eyes and 83.5      3.9     in the fellow eyes. Statistically significant difference was not seen between the groups (P  >  0.05). Mean RNFL and mean CMT measurements were also similar in two groups (P  >  0.05). Subfoveal CT, CMT, RNFL, and GCC thickness measurements were not statistically significant between @entity735 .

title: Evaluation of the retinal ganglion cell and choroidal thickness in young Turkish adults with hyperopic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['hyperopic anisometropic amblyopic eyes and normal fellow eyes']

entities_list: @entity2194 :: ('MESH:D005128', 'Disease') :: ['choroidal thickness (CT) and ganglion cell complex (GCC) thickness of the normal fellow eyes']

entities_list: @entity4457 :: ('MESH:D000550', 'Disease') :: ['anisometropic amblyopia']

answer: @entity4457 :: (MESH:D000550,Disease) :: ['anisometropic amblyopia']


abstract: OBJECTIVE: To study effects of autogenous femoral head bone grafting combined with total hip replacement for the treatment of old center dislocation of @entity572 , and to evaluate the superiority of acetabular defect reconstruction with autogenous bone. METHODS: From March 2008 to December 2013, 16 @entity1 (16 hips) with old center dislocation of @entity572 were treated with autologous bone graft combined with total hip replacement. There were 11 males and 5 females, ranging in age from 41 to 72 years old, with an average of 56.3 years old. The duration of the disease ranged from 3.6 to 37.2 years. Twelve @entity1 had @entity130 caused by traffic accidents and 4 @entity1 were caused by falling down. The @entity572 @entity158 at the first month after operation, Harris score and @entity572 movement of all @entity1 were observed by using electronic case follow-up system. RESULTS: All the @entity1 were followed up, and the duration ranged from 11 to 78 months, with an average of 27.3 months. The postoperative @entity572 movement of (56.2  23.4)   VAS 86.3  7.2 and Harris score 32.6  12.6 were all better than preoperative (181.8  17.6)  , 11.1  2.6 and 86.3  7.2. The joint @entity158 was reduced and the function limitation was improved after operation, and the prosthesis position was good. CONCLUSION: When the autologous femoral head bone grafting combined with total hip arthroplasty is used to treat old @entity572 , the initial and long-term stability of acetabular bone grafting is good, and the technique can avoid allogeneic bone complications, bone source rationally and reduce the economic burden of @entity1 .

title: [Autogenous femoral head bone grafting combined with total hip arthroplasty for the treatment of old dislocation of XXXX in 16 cases].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity572 :: ('MESH:D006617', 'Disease') :: ['hip joint', 'hip central dislocation']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['injuries']

answer: @entity572 :: (MESH:D006617,Disease) :: ['hip joint center']


abstract: BACKGROUND: Values of hematological parameters are affected by factors such as age, sex, ethnic background and social, nutritional and environmental factors. The objective of this study was to determine the values of hematological parameters, red cell indices and @entity13554 and Hb F levels in normal Saudi @entity1 , living in the Central Province of Saudi Arabia. MATERIALS AND METHODS: The study was carried out on 1526 apparently healthy @entity1 , with ages ranging from 1-15 years, and selected during a household screening program. Hematological parameters, red cell indices, and hemoglobin types ( @entity13554 and Hb F) were estimated, and the @entity1 were divided into 15 groups depending on the age. Male and female @entity1 were separated, and the mean and standard deviation of each parameter was calculated for each age group. RESULTS: No significant differences were observed in the red cell count in the male and female @entity1 . White blood cells gradually decreased from 2 years onwards, while hemoglobin and hematocrit levels increased significantly from 2 to 15 years. Mean cell volume and mean cell hemoglobin also showed slight increases, while mean cell hemoglobin concentration remained more or less constant. Hemoglobin A2 and Hb F showed slight but nonsignificant fluctuations. Comparison of the results with those reported in the literature shows that Saudi @entity1 have some values similar to Caucasians, while others have values which are intermediate between Caucasians and African @entity1 . CONCLUSION: The values reported in this study can be used as normal reference values for Saudi @entity1 and adolescents.

title: Normal reference values for hematological parameters, red cell indices, XXXX and HB F from early childhood through adolescence in Saudis.

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

answer: @entity13554 :: (3040,Gene) :: ['HB A2']


abstract: PURPOSE: Bevacizumab has demonstrated survival benefit in metastatic @entity14 (mCRC) @entity1 when combined with chemotherapy. Several randomized clinical studies have evaluated bevacizumab in combination with chemotherapy. Meta-analysis was performed to better assess the efficacy and safety of bevacizumab with chemotherapy for mCRC. MATERIALS AND METHODS: Five clinical trials randomizing a total of 3,103 mCRC @entity1 to chemotherapy alone or to the combined treatment of chemotherapy plus bevacizumab were identified. The efficacy data included progression-free survival (PFS), overall survival (OS), and overall response rate (ORR), and the safety data contained the 60-day all-cause mortality rate, adverse events (AEs), and specific @entity137 such as @entity101 , @entity715 , @entity548 , @entity644 , @entity344 , @entity294 , and @entity1210 . RESULT: There was a significant PFS benefit (P = 0.00; hazards ratio [HR] = 0.66) and OS benefit (P = 0.00; HR = 0.77) in favor of the combined treatment. The ORR was significantly higher on the bevacizumab-containing arm (P = 0.021; relative risk [RR] = 1.5), while CR was comparable between the two arms (P = 0.09). A higher incidence of grade 3/4 AEs, grade 3/4 @entity101 , grade 3/4 @entity1031 /thrombotic events, grade 3/4 @entity548 , and @entity344 was associated with the bevacizumab group. The two treatment groups were similar in terms of grade 3/4 @entity644 , grade 3/4 @entity1431 , grade 3/4 @entity294 , and the 60-day all-cause mortality rate. CONCLUSION: The addition of bevacizumab to chemotherapy confers a clinically meaningful and statistically significant improvement in OS, PFS, and ORR. Its side effects are predictable and manageable and do not compound the incidence or severity of @entity137 from chemotherapy.

title: A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic XXXX .

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal perforation']

entities_list: @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic']

entities_list: @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

entities_list: @entity1210 :: ('MESH:C536227', 'Disease') :: ['leucopenia']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: BACKGROUND: Denovo @entity30 ( @entity30 ) develops in 5% to 10% of @entity1 after ileal pouch-anal @entity254 (IPAA) for @entity31 ( @entity31 ) leading to increased morbidity and rates of pouch failure. Initial nonbloody @entity294 and @entity353 at diagnosis are independent risk factors for a change in diagnosis from @entity31 to @entity30 in nonsurgical @entity1 . We investigated whether these features were risk factors for denovo @entity30 in a longitudinal cohort of @entity1 with @entity31 undergoing IPAA. METHODS: Prospective profiles of @entity1 with @entity31 undergoing IPAA followed over a 22-year period by 1 surgeon were analyzed. Denovo @entity30 was diagnosed when @entity32 (5 or more @entity1066 ) involved the small bowel mucosa proximal to the ileal pouch any time after surgery and/or when a pouch @entity292 or other perianal complication developed more than 3 months after ileostomy closure. @entity1 with @entity29 unclassified, acute @entity5042 , chronic @entity5042 , and those lost to follow-up were excluded from analysis. Cox regression analysis was performed for statistical significance. RESULTS: Of the 199 study @entity1 included in the analysis, denovo @entity30 developed in 42 @entity1 (21%). @entity1 who developed denovo @entity30 had an increased incidence of nonbloody @entity294 (n = 12; 29%) compared with @entity1 who had no evidence of pouch @entity32 (n = 25; 16%) (P = 0.03). In contrast, the incidence of @entity353 was not significantly increased in @entity1 with denovo @entity30 (n = 7; 17%) compared with @entity1 who never had pouch @entity32 (n = 16; 10%) (P = 0.12). CONCLUSIONS: Initial nonbloody @entity294 is associated with denovo @entity30 after IPAA. This association warrants close consideration before surgery.

title: Nonbloody @entity294 but Not Significant Weight Loss at Diagnosis Is Associated with the Development of Denovo @entity30 After Ileal Pouch-anal XXXX for @entity31 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'mucosal inflammation']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

entities_list: @entity5042 :: ('MESH:D019449', 'Disease') :: ['pouchitis']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'UC']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ['CD', "Crohn's disease"]

answer: @entity254 :: (MESH:C563598,Disease) :: ['Anastomosis']


abstract: @entity303 in @entity304 is caused by a variety of central nervous system (CNS) lesions, of which the molecular and pathogenic causes are poorly understood but probably include: 1. @entity528 in dopaminergic, noradrenergic, serotonergic, cholinergic or multiple systems including the amygdyloid nucleus; 2. limbic and/or cortical @entity195 and/or Lewy body pathologies, with loss of synapses and neurons, and 3. a combination of these lesions or additional CNS pathologies. In general, degeneration of subcortical @entity528 appears insufficient to induce severe mental decline although, occasionally, @entity73 occurs without apparent @entity75 . On the other hand, neuritic cortical @entity195 showing similar or differential distribution compared to @entity195 ( @entity195 ) displays a significant linear correlation with @entity303 in @entity304 . Plaques can be associated with cortical Lewy bodies and, the contribution of each to dementing processes remains unresolved. In a consecutive autopsy series of 610 @entity1 with @entity304 , the total prevalence of retrospectively assessed @entity303 was 34.6%. In @entity191 ( @entity191 ) of the Lewy body type, it was 30.2%, mostly associated with other @entity75 , mainly @entity195 , while only 3.5% of "pure" @entity191 without additional brain pathologies were demented. There was no significant difference in age and duration of illness between demented and non- @entity191 @entity1 . Secondary @entity191 showed a higher incidence of @entity303 (56.3%), again with predominant @entity195 which was present in 73% of the total of demented @entity191 @entity1 and in almost 82% of the @entity191 cases in this series. The specific contribution of cortical and @entity75 to @entity73 in @entity304 , their relationship to @entity195 , and an etiology await further elucidation.

title: Morphological substrates of @entity303 in XXXX . A critical update.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity304 :: ('MESH:D010302', 'Disease') :: ['Parkinsonism', 'parkinsonism']

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['Dementia', 'dementia']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment', 'mental impairment']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['cortical lesions', 'brain lesions', 'subcortical lesions']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", 'demented PD', 'parkinsonian', 'parkinsonian syndromes', 'PD']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['Alzheimer', 'AD', "Alzheimer's disease", 'Alzheimer pathology', 'Alzheimer change']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal networks', 'Degeneration of subcortical ascending systems with neuronal losses']

answer: @entity304 :: (MESH:D010302,Disease) :: ['parkinsonism']


abstract: The reproductive success of wild birds has been affected by exposure to multiple contaminants. Reproduction of captive @entity41376 ( @entity41376 ) was suppressed when adult birds were exposed to dietary @entity3215 ( @entity3215 ). In this study, the reproductive effects of in ovo exposure to @entity3215 is explored, along with determining effects on reproduction in second-generation birds indirectly exposed to @entity3215 . Reproductive changes in this subsequent generation are examined separately in male and female birds. Captive @entity41376 (F. sparerius) were hatched from clutches with eggs containing environmentally relevant levels of total @entity3215 (34.0 microg/g whole egg WW versus 0 microg/g controls); parent birds had been fed @entity5241 -spiked (Aroclor 1248:1254:1260) food (7 mg/kg BW day(-1)) for 100 days until their eggs hatched. In 1999, the second-generation @entity5241 birds were paired with unexposed kestrels having reproductive experience. In ovo @entity5241 exposure suppressed egg laying completely in 25% of @entity5241 females and resulted in delays in clutch initiation and smaller clutch sizes for @entity5241 male and female pairs. There was no evidence in this study of in ovo @entity5241 treatment effects on fertility or hatching success. The decline in reproductive success was also reflected in the reduced fledging success and higher incidence of complete brood mortality of @entity5241 nestlings. Differences between in ovo-exposed @entity5241 males and females but not between controls were evident in reproductive success. In ovo @entity5241 exposure appears to have had greater effects on female kestrels until clutch completion, with a greater time lag between pairing and egg laying, reduced numbers of pairs laying eggs, and smaller clutches being laid. In ovo @entity5241 exposure has greater effects later in the breeding season on male kestrels, which had poorer hatching and fledging success relative to the @entity5241 females. Possible behavioral and physiological mechanisms involved in these reproductive changes are discussed.

title: In ovo exposure to XXXX : reproductive effects on second-generation @entity41376 .

entities_list: @entity41376 :: ('56350', 'Species') :: ['Falco sparverius', 'American kestrels']

entities_list: @entity3215 :: ('MESH:D011078', 'Chemical') :: ['polychlorinated biphenyls', 'PCBs']

answer: @entity3215 :: (MESH:D011078,Chemical) :: ['polychlorinated biphenyls']


abstract: BACKGROUND: There are a wide range of drugs including antidepressants, anticonvulsants and antipsychotics that cause embryonic @entity1168 in vitro but it is unknown if they have a similar effect in vivo. One way to verify whether these in vitro findings are replicated in vivo is by the use of ultrasound examination of dosed pregnant @entity35 . We tested this by examining the effect of @entity2781 on embryonic heart rate (HR) in vivo using ultrasound. METHODS: @entity35 were dosed with @entity2781 (4 or 2.5 mg/kg) on GD11 or (5 or 2.5 mg/kg) on GD13 and embryonic HR assessed by ultrasound, 2 and 24 hr later. Fetuses were examined for @entity600 on GD20. RESULTS: HR of control @entity35 embryos showed a wide range at each gestational day. Dosing with @entity2781 on GD11 caused severe @entity1168 (   60% reduction) 2 hours after dosing with recovery after 24 h of >60% of LD but death and slow HR among the @entity2033 embryos. At term, 32% of the LD surviving fetuses had hypoplastic upper lip while >90% of @entity2033 embryos had died. On GD13, embryonic HR was reduced in a dose-dependent manner with >85% of LD and @entity2033 recovered by 24 hr. At term, all LD fetuses were normal while 29% of @entity2033 fetuses had @entity4218 . CONCLUSIONS: Ultrasound is a useful technique to investigate the effect of maternally administered drugs on the embryonic HR in the @entity35 . The results may provide more information about the safety of these drugs in pregnancy leading to better risk assessment for the @entity1 .

title: The Effect of XXXX on the Heart Rate of GD11 and GD13 @entity35 Embryos, in vivo, Using Ultrasound.

entities_list: @entity2781 :: ('MESH:C063533', 'Chemical') :: ['dofetilide']

entities_list: @entity4218 :: ('MESH:D017880', 'Disease') :: ['limb defects']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['malformations']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']

answer: @entity2781 :: (MESH:C063533,Chemical) :: ['Dofetilide']


abstract: PURPOSE: Our aim was to evaluate the safety and efficacy of percutaneous nephrolithotomy (PCNL) with ultrasonography (US)-guided renal access in the @entity812 . @entity1 AND METHODS: From July 2006 to March 2008, 40 @entity1 with @entity1290 > 2 cm underwent PCNL with US-guided renal access in the @entity812 by a single surgeon. We report our technique and the outcomes in detail. RESULTS: Successful access was achieved in 40 @entity1 (100%). Complete stone clearance rate was 85% (34 @entity1 ). After surgery, six (15%) @entity1 had stones (6-11 mm) detected by plain abdominal radiography or sonography and were referred for shockwave lithotripsy. The mean stone size was 29 mm (range 22-43 mm). The mean operative time was 45 minutes (range 32-75 min), and the mean hospital stay was 2.8 days (range 2-4 d). Postoperative US did not reveal considerable fluid collection. There were no visceral injuries. Also, there was no significant @entity548 that led to transfusion intraoperatively and postoperatively. CONCLUSION: PCNL with US-guided renal access in the @entity812 is safe and convenient, and prevents harmful effects of radiation for the surgeon, the surgical team, and the @entity1 .

title: Percutaneous nephrolithotomy with ultrasonography-guided renal access in the XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity1290 :: ('MESH:D007669', 'Disease') :: ['renal stones']

entities_list: @entity812 :: ('MESH:D021501', 'Disease') :: ['lateral decubitus flank position']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

answer: @entity812 :: (MESH:D021501,Disease) :: ['lateral decubitus flank position']


abstract: OBJECTIVES: To evaluate the additional analgesic efficacy of the rectal administration of @entity3522 suppository compared with placebo in @entity1 undergoing transrectal ultrasound-guided prostate biopsy. METHODS: A total of 40 consecutive @entity1 undergoing biopsy were enrolled in this study. @entity1 were randomized equally into two treatment groups. In group 1, @entity1 received an intrarectal 100-mg @entity3522 suppository 1 hour before biopsy. In group 2, @entity1 received a glycerin suppository as a placebo intrarectally 1 hour before biopsy. All @entity1 received 10 mL of 2% @entity3303 gel intrarectally 10 minutes before biopsy. A self-administrated visual analog scale was used to measure the @entity158 scores at the end of the biopsy and 2 hours and 1 day after the biopsy. RESULTS: The mean @entity1 age was 63.3 +/- 6.8 years and 61.6 +/- 6.7 years in groups 1 and 2, respectively. The mean @entity158 score in groups 1 and 2 was 3.4 +/- 1.3 versus 5.9 +/- 1.7 (P < 0.0001), respectively, at the end of the biopsy. The mean @entity158 score at 2 hours and 1 day after the procedure was 1.2 +/- 1.0 versus 3.6 +/- 1.4 (P < 0.0001) and 0.5 +/- 0.9 versus 1.4 +/- 1.3 (P = 0.017) in groups 1 and 2, respectively. CONCLUSIONS: Intrarectal @entity3522 suppository administration is a simple, safe, and effective procedure to reduce @entity158 and improve @entity1 ' tolerance of transrectal ultrasound-guided prostate biopsy. We recommend intrarectal @entity3522 suppository administration, together with intrarectally administered @entity3303 gel, in @entity1 undergoing transrectal ultrasound-guided prostate biopsy.

title: @entity3522 suppository administration in conjunction with XXXX gel during transrectal ultrasound-guided prostate biopsy: prospective, randomized, placebo-controlled study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'men']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine']

entities_list: @entity3522 :: ('MESH:D004008', 'Chemical') :: ['diclofenac']

answer: @entity3303 :: (MESH:D008012,Chemical) :: ['lidocaine']


abstract: @entity261 is one of the few remaining hormonal insufficiency states for which replacement therapy is unavailable. Previous short-term controlled trials have shown @entity461 to be a safe and effective treatment of @entity261 . In this randomized, parallel group, open-label trial, we compared synthetic @entity1 @entity461 -(1-34) ( @entity461 ) with conventional therapy, @entity3873 and @entity460 , over a 3-yr period. Twenty-seven @entity1 with confirmed @entity261 , aged 18-70 yr, were randomized to either twice daily sc @entity461 or oral @entity3873 and @entity460 . The primary end points were @entity460 levels in serum and urine. Secondary end points were @entity1011 clearance, markers of @entity79 , and bone mineral density. Throughout the 3-yr study period, serum @entity460 levels were similar in both treatment groups within or just below the normal range. Mean urinary @entity460 excretion was within the normal range from 1-3 yr in @entity461 -treated @entity1 , but remained above normal in the @entity3873 group. Bone mineral content and bone mineral density showed no significant between-group differences over the 3-yr study period. We conclude that treatment with twice daily sc @entity461 provides a safe and effective alternative to @entity3873 therapy and is able to maintain normal serum @entity460 levels without @entity5200 for at least 3 yr in @entity1 with @entity261 .

title: Long-term treatment of @entity261 : a randomized controlled study comparing parathyroid hormone-(1-34) versus XXXX and @entity460 .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity3873 :: ('MESH:D002117', 'Chemical') :: ['calcitriol']

entities_list: @entity261 :: ('MESH:D007011', 'Disease') :: ['Hypoparathyroidism', 'hypoparathyroidism']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone turnover']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity5200 :: ('MESH:D053565', 'Disease') :: ['hypercalciuria']

answer: @entity3873 :: (MESH:D002117,Chemical) :: ['calcitriol']


abstract: PURPOSE: To assess the upper eyelid kinematics during spontaneous blinking in unilateral @entity8442 before and after upper eyelid load with gold weight (GW) or autogenous temporalis fascia (TF) sling. DESIGN: Comparative case series. SUBJECTS: @entity1 with long-standing unresolved unilateral @entity3541 who underwent surgical treatment with GW (n   =   8) or upper lid cerclage with TF (n   =   10). The contralateral eyelid served as the control for each @entity1 (control group). METHODS: Preoperative and postoperative measurements of spontaneous blink kinematics with magnetic search coil and clinical assessment of lid margin position, lagophthalmos and ocular surface exposure, and determine amplitude, maximum velocity and main sequence of spontaneous blinks; relative amplitude of blinks to the pupil center; ocular surface exposure scores; magnitude of lagophthalmos and mid-pupil lid distances. RESULTS: The mean (  SE) down-phase amplitude ratio between paralyzed and contralateral eyelids ( @entity1017 ) was 10.0% preoperatively for both groups and significantly increased to 29        6% for the GW group (p   <   0.05) and 23        4% for the TF group (p   <   0.05). At 6 months the gain was significant for the GW group only (32        7%, p   <   0.05). There was no effect on the maximum velocity of the blinks or the main sequence of paretic and contralateral blinks with either surgery. Both procedures lowered the lid margin increasing the number of blinks that reached the pupil center. At 6 months this effect was prominent only for the GW group. @entity2372 scores and lagophthalmos decreased postoperatively especially in the GW group. CONCLUSIONS: The beneficial effect of lid load surgeries result from a combination of a small increase on the spontaneous blink amplitude and a static effect due to the reduction of the distance between the lid margin and pupil center.

title: Spontaneous Blinking Kinetics on XXXX After Lid Load with Gold Weight or Autogenous Temporalis Fascia Sling.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patient']

entities_list: @entity2372 :: ('MESH:C562399', 'Disease') :: ['Exposure keratopathy']

entities_list: @entity8442 :: ('MESH:D007418', 'Disease') :: ['paralytic lagophthalmos']

entities_list: @entity1017 :: ('MESH:D015430', 'Disease') :: ['blink gain']

entities_list: @entity3541 :: ('MESH:D005158', 'Disease') :: ['facial palsy']

answer: @entity8442 :: (MESH:D007418,Disease) :: ['Paralytic Lagophthalmos']


abstract: Increased @entity633 is a hallmark of early @entity2316 , whereas the role of immunoglobulins (Igs), such as IgG (its 1-4 subtypes), IgA, and IgM, different in charge and size, has not been examined in early @entity8 in the past due to lack of a sensitive and reliable method. Our study group consisted of subjects with @entity1723 ( @entity1723 ) and normoalbuminuria (n = 78), microalbuminuria (n = 78), and of 75 @entity392 ( @entity392 ). A Luminex-based immunoassay (1,000 time more sensitive than nephelometry-based method) was validated for the urine matrix and used for the measurements of IgG1-4, IgA, and IgM in our study groups. The Luminex-based assay detected Igs in 87% of @entity392 subjects and in 100% of @entity1723 subjects. Recovery of known amounts of Igs added to urine was 92-118%. In the normoalbuminuria group, urinary concentrations of albumin, IgG2, IgA, and IgM were significantly higher than in @entity392 , whereas in the microalbuminuria, further elevation of IgG2, IgG4, and IgA was the most pronounced. In all three groups, fractional excretion of Igs was at least 100 times lower than that of albumin. Fractional excretion of IgG2 was the highest among all Igs. We validated a sensitive method for measuring Igs in urine using Luminex. We found that elevated concentrations of Igs, particularly in IgG2 and IgA, is present in subjects with @entity1723 and no @entity644 . Elevation of those particular Ig subtypes suggests a contribution of novel mechanisms in early @entity2316 , different from charge and size barrier impairment.

title: Elevated urinary excretion of immunoglobulins in nonproteinuric patients with XXXX .

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy']

entities_list: @entity2316 :: ('MESH:D003928', 'Disease') :: ['diabetic nephropathy']

entities_list: @entity633 :: ('MESH:D000419', 'Disease') :: ['albuminuria']

entities_list: @entity1723 :: ('MESH:D003922', 'Disease') :: ['T1D', 'type 1 diabetes']

entities_list: @entity392 :: ('MESH:D014012', 'Disease') :: ['HS', 'healthy subjects']

answer: @entity1723 :: (MESH:D003922,Disease) :: ['type 1 diabetes']


abstract: OBJECTIVE: To extend the molecular analysis of the @entity70528 intronic @entity3745 (TG) mutation, and to report the eleven year follow-up of the affected @entity1 . METHOSD: Two siblings with severe @entity6750 with fetal and @entity5651 , harboring the @entity70528 mutation were included. Nodular and non-nodular thyroid tissue specimens were collected. Specific thyroid genes expression was evaluated by real-timePCR and by immunohistochemistry. RESULTS: In non-nodular tissue specific thyroid genes mRNA were reduced when compared to normal thyroid sample. In the nodule, @entity5787 and NIS expression was very low. Microscopic examinations showed very large follicular-lumina and swollen vesicles of endoplasmatic-reticulum. Strong cytoplasmatic and low follicular-lumen TG immunostaining were detected. Intracellular NIS, membrane @entity5787 and @entity5010 immunostaining had higher positivity in non-nodular sample. Both @entity1 had a long-term adequate developmental outcome, besides one @entity1 have been lately-treated. CONCLUSIONS: @entity70528 mutation not only lead to very enlarge endoplasmatic-reticulum, but also to alterations of specific thyroid genes expression. The clinical evolution of @entity1 harboring these mutations strengthen the concept of the influence of environment, like @entity1496 nutrition, to determine the final phenotypic appearance.

title: A molecular analysis and long-term follow-up of two siblings with severe @entity6750 carrying the XXXX intronic @entity3745 mutation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5651 :: ('MESH:D006042', 'Disease') :: ['neonatal goiter']

entities_list: @entity6750 :: ('MESH:D003409', 'Disease') :: ['congenital hypothyroidism']

answer: @entity70528 :: (c|SUB|G|IVS30+1|T,DNAMutation) :: ['IVS30+1G>T']


abstract: UNASSIGNED: The antipsychotics @entity1090 , @entity1770 and @entity7299 are frequently prescribed for the treatment in @entity1 with @entity2438 . The aim of this study was to validate an ultra-high performance liquid chromatography-mass spectrometry method for the quantification of these antipsychotics in plasma. An ultra-high performance liquid chromatography-mass spectrometry assay was developed for the determination of the drugs and metabolites. Gradient elution was performed on a reversed-phase column with a mobile phase consisting of @entity6190 , @entity5189 in @entity1042 or in Milli-Q ultrapure water at a flow rate of 0.5   mL/min. The method was validated according to the US Food and Drug Administration guidelines. The analytes were found to be stable enough after reconstitution and injection of only 5    L improved the accuracy and precision in combination with the internal standard. Calibration curves of all five analytes were linear. All analytes were stable for at least 72   h in the autosampler and the high quality control of @entity7302 was stable for 48   h. The method allows quantification of all analytes. The advantage of this method is the combination of a minimal injection volume, a short run-time, an easy sample preparation method and the ability to quantify all analytes in one run. Copyright    2015 John Wiley _ Sons, Ltd.

title: Identification and quantification of the antipsychotics @entity1090 , XXXX , @entity7299 and their major metabolites in plasma using ultra-high performance liquid chromatography-mass spectrometry.

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity7302 :: ('MESH:C079150', 'Chemical') :: ['9-OH-risperidone']

entities_list: @entity1042 :: ('MESH:D000432', 'Chemical') :: ['methanol']

entities_list: @entity6190 :: ('MESH:C018824', 'Chemical') :: ['ammonium acetate']

entities_list: @entity7299 :: ('MESH:C005569', 'Chemical') :: ['pipamperone']

entities_list: @entity1770 :: ('MESH:C094645', 'Chemical') :: ['aripiprazole']

entities_list: @entity5189 :: ('MESH:C030544', 'Chemical') :: ['formic acid']

entities_list: @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone']

answer: @entity1770 :: (MESH:C094645,Chemical) :: ['aripiprazole']


abstract: PURPOSE: Low dose rate radioemitters, such as 125I, 103Pd, and 89Sr, have been used both for @entity263 . Most normal cells exposed to ionizing radiation characteristically activate cell cycle checkpoints, resulting in cell cycle arrest at the G1/S and G2/M transition points. @entity5 cells are typically quite sensitive to radiation killing late in the G2 phase of the replicative cell cycle. Furthermore, most @entity5 cells accumulating at the G2/M transition point as a result of low dose rate radiation exposure appear to become sensitive to further low dose rate irradiation. For this reason, protracted exposure of @entity5 cells to low dose rate radiation has been proposed to result in increased @entity5 cell killing as compared with brief exposures of @entity5 cells to high dose rate radiation. Since many @entity1 @entity263 contain somatic genome alterations targeting genes which affect the cell cycle and radiation-associated cell cycle checkpoints, we evaluated the effects of low dose rate radiation exposure on the cell cycle and on clonogenic survival for various @entity1 @entity263 cell lines. MATERIALS AND METHODS: @entity1 @entity263 cells from the LNCaP, DU 145, PC-3, PPC-1, and TSU- @entity35 cell lines were exposed to low dose rate (0.25 Gy/hour) or high dose rate (60 Gy/hour) radiation in vitro and then assessed for radiation @entity137 by clonogenic survival assay. Cell cycle perturbations following protracted exposure to low dose rate radiation were evaluated using flow cytometry. RESULTS: For LNCaP cells, low dose rate radiation exposure resulted in an accumulation of cells at both the G1/S and the G2/M cell cycle transition points. For DU 145, PC-3, PPC-1, and TSU- @entity35 cells, treatment with low dose rate radiation triggered G2/M cell cycle arrest, but not G1/S arrest. Unexpectedly, the cell cycle redistribution pattern phenotypes observed, G1/S and G2/M cell cycle arrest versus G2/M arrest alone, appeared to have little effect on low dose rate radiation survival. Furthermore, while PC-3, PPC-1, and TSU- @entity35 cells exhibited increased cytotoxic sensitivity to low dose rate versus fractionated high dose rate radiation treatment, DU 145 and LNCaP cells did not. CONCLUSIONS: Radiation-associated pertubations in replicative cell cycle progression were not dominant determinants of low dose rate radiation killing efficacy in @entity1 @entity263 cell lines in vitro.

title: Sensitivity of @entity1 XXXX cell lines to low dose rate radiation exposure.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostatic carcinoma', 'prostate cancer', 'prostatic carcinomas', 'local and systemic treatment of prostate cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Cancer']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostatic carcinoma']


abstract: OBJECTIVES: To study the effects of a one-year physical activity programme on aerobic capacity, physical activity and health-related quality of life (HRQL) in @entity1 with @entity1252 ( @entity1252 ) by a randomized control design. METHODS: Thirty-five @entity1 with @entity258 activity and organ damage were randomized to intervention (I) or control (C) group. The intervention during months 0-3 consisted of education, supervised aerobic exercise at high intensity and individual @entity15285 , as well as self-managed physical activity at low-to-moderate intensity. During months 4-12, the physical activity was self-managed and the @entity15285 was successively reduced over time. Outcome measures included: maximal @entity26 uptake (VO2 max) from a bicycle ergometer test, self-reported physical activity and HRQL (SF-36). RESULTS: VO2 at sub-max. and max. increased, independent of group, during the one-year study period (main effect of time p   <   0.0001). VO2 max. increased between baseline and month 3 (p   <   0.0001), between months 3 and 6 (p   =   0.01) and the increase was sustained at month 12 (ns). Frequency of physical activity at high intensity also increased, independent of group, during the study period. It was increased at months 3, 6 and 12 compared to baseline (p   =   0.02, p   <   0.001, p   =   0.03). Improvement in mental health between baseline and month 6 (p   =   0.002) was seen for the I-group, not the C-group (p   =   0.03). Disease activity and organ damage did not change. CONCLUSIONS: Physical activity and aerobic capacity increased after supervised exercise and @entity15285 , and the improvement was sustained during the one-year programme. However, no interactions between the group differences were seen, which suggests that repeated measurements could motivate to increased physical activity and thereby to increased aerobic capacity. As sub-max. VO2 increased over time, training-induced changes in VO2 on-kinetics could be another explanation. Little influence on HRQL was seen after the programme. The study indicates that physical activity at high intensity over one year is tolerated by @entity1 with mild to moderate @entity1252 .

title: Effects of a one-year physical activity programme for XXXX with @entity1252 - a randomized controlled study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus']

entities_list: @entity258 :: ('MESH:D009800', 'Disease') :: ['low or moderate disease']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: BACKGROUND: @entity1289 ( @entity1289 ) inhibitors reduce urine protein excretion and slow the progression of @entity8 . The beneficial effect in slowing the progression of @entity8 is greater in @entity1 with higher urine protein excretion at the onset of treatment. We hypothesized that the greater beneficial effect of @entity1289 inhibitors on the progression of @entity8 in @entity1 with higher baseline levels of @entity644 is due to their greater antiproteinuric effect in these @entity1 . METHODS: Data were analyzed from 1860 @entity1 enrolled in 11 randomized controlled trials comparing the effect of antihypertensive regimens, including @entity1289 inhibitors to regimens not including @entity1289 inhibitors on the progression of @entity2316 . Multivariable linear regression analysis was used to assess the relationship between the level of @entity644 at baseline and changes in urine protein excretion during follow-up. The Cox proportional hazards analysis was used to assess the relationship between changes in urine protein excretion during follow-up and the effect of @entity1289 inhibitors on the time to doubling of baseline serum @entity1011 values or onset of @entity454 . RESULTS: Mean (median) baseline urine protein excretion was 1.8 (0.94) g/day. @entity1 with higher baseline urine protein excretion values had a greater reduction in @entity644 during the follow-up in association with treatment with @entity1289 inhibitors and in association with lowering @entity551 (interaction P < 0.001 for all). A higher level of urine protein excretion during follow-up (baseline minus change) was associated with a greater risk of progression [relative risk 5.56 (3.87 to 7.98) for each 1.0 g/day higher protein excretion]. After controlling for the current level of urine protein excretion, the beneficial effect of @entity1289 inhibitors remained significant [relative risk for @entity1289 inhibitors vs. control was 0.66 (0.52 to 0.83)], but there was no significant interaction between the beneficial effect of @entity1289 inhibitors and the baseline level of urine protein excretion. CONCLUSIONS: The antiproteinuric effects of @entity1289 inhibitors and lowering blood pressure are greater in @entity1 with a higher baseline urine protein excretion. The greater beneficial effect of @entity1289 inhibitors on @entity8 progression in @entity1 with higher baseline @entity644 can be explained by their greater antiproteinuric effects in these @entity1 . The current level of urine protein excretion is a modifiable risk factor for the progression of @entity2316 . @entity1289 inhibitors provide greater beneficial effect at all levels of current urine protein excretion.

title: XXXX as a modifiable risk factor for the progression of @entity2316 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal disease']

entities_list: @entity1289 :: ('1636', 'Gene') :: ['ACE', 'Angiotensin-converting enzyme']

entities_list: @entity2316 :: ('MESH:D003928', 'Disease') :: ['non-diabetic renal disease']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['systolic and diastolic blood pressures']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease']

answer: @entity644 :: (MESH:D011507,Disease) :: ['Proteinuria']


abstract: BACKGROUND: @entity3852 is a rare @entity1489 of neuroendocrine origin, which is characterized by a high rate of recurrence, metastatic spread and mortality. Because of its rarity, evidence-based therapeutic regimens are difficult to establish. @entity3852 is known to be both radio- and chemosensitive. @entity137 is a key factor in assessing any regimen, as the @entity1 are usually elderly and likely to have other significant medical problems. @entity1 AND METHODS: We retrospectively evaluated five @entity1 with metastatic @entity3852 to see if liposomal @entity632 (Caelyx) or Myocet) in combination with radiotherapy exhibited clinical anti-tumoral effects accompanied by acceptable side effects. RESULTS: The outpatient chemotherapy regimen was tolerated without major side effects and produced good response rates. All @entity1 achieved at @entity5 stabilization; four of five had a partial remission. Effects of therapy were usually seen in the first cycle of therapy but the responses were of short duration with an average interval of two months until progression. CONCLUSIONS: As combined radiochemotherapy with liposomal @entity632 is well tolerated even in older @entity1 with other illnesses and can be given on an outpatient basis, it is an attractive option for metastatic @entity3852 . Based on response rate or overall survival, it offers no advantages compared to polychemotherapy.

title: Therapy of metastasized @entity3852 with liposomal XXXX in combination with radiotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity3852 :: ('MESH:D015266', 'Disease') :: ['Merkel cell carcinoma']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['least tumor']

entities_list: @entity1489 :: ('MESH:D012878', 'Disease') :: ['skin cancer']

answer: @entity632 :: (MESH:D004317,Chemical) :: ['doxorubicin']


abstract: OBJECTIVES: To describe and analyze the intubating conditions and hemodynamic effects of @entity4671 in @entity1 undergoing @entity1170 ( @entity1170 ) in the emergency department. METHODS: The authors conducted a prospective observational study of all @entity1 who received @entity4671 for induction of @entity1170 over a 42-month period in a large tertiary care teaching hospital. Intubating conditions were determined by the emergency physician for both sedation and @entity912 and for technical difficulty using a five-point Likert scale. Hemodynamic effects were evaluated before, after, and every five minutes for 15 minutes following administration of @entity4671 . RESULTS: @entity4671 was used for induction of @entity1170 in 522 @entity1 , all of whom were included in the final efficacy analysis, while 491 were included in the analysis of hemodynamics. @entity3303 and @entity3575 were used as pretreatment in 65.1% and 26.1% of @entity1 , respectively, while @entity2900 was the paralytic in 94.3% of intubations. Sedation and @entity912 were rated as excellent or good in 88.1% and 8.8% of @entity1 , respectively, while technical difficulty was very easy or easy in 60.7% and 19.0% of @entity1 , respectively. Mean (+/- SD) baseline systolic blood pressure (sBP), diastolic blood pressure (dBP), and heart rate were found to be 132.7 (+/- 35.4) mm Hg, 69.5 (+/- 21.2) mm Hg, and 96.1 (+/- 26.2) bpm, respectively. Overall, there was a clinically insignificant elevation in sBP (p < 0.0001), @entity11559 (p = 0.0002), and heart rate (p < 0.0001) immediately postintubation. Elevations in sBP persisted at five minutes (p = 0.0230) and ten minutes (p = 0.0254) postintubation. Diastolic blood pressure and heart rate returned to baseline at five minutes after intubation and remained stable throughout the 15-minute postintubation assessment period. In the subgroup of 80 @entity1 with a preintubation sBP < 100 mm Hg, there was a 12.1-mm Hg elevation in sBP (p < 0.0001) and a 7.3-mm Hg elevation in dBP (p = 0.0001) immediately postintubation. This elevation persisted throughout the 15-minute postintubation assessment period. CONCLUSIONS: @entity4671 appears to provide appropriate intubating conditions in a heterogeneous group of @entity1 undergoing @entity1170 in the emergency department. Hemodynamic stability appears to be present following administration of this agent, even in @entity1 with low pre- @entity1170 blood pressure. This attribute must be weighed against potential adverse effects of this agent, including adrenal suppression.

title: Intubating conditions and hemodynamic effects of @entity4671 for XXXX in the emergency department: an observational cohort study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1170 :: ('MESH:C564983', 'Disease') :: ['RSI', 'rapid sequence intubation']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['Lidocaine']

entities_list: @entity4671 :: ('MESH:D005045', 'Chemical') :: ['etomidate', 'Etomidate']

entities_list: @entity3575 :: ('MESH:D005283', 'Chemical') :: ['fentanyl']

entities_list: @entity912 :: ('MESH:D010243', 'Disease') :: ['paralysis']

entities_list: @entity2900 :: ('MESH:D013390', 'Chemical') :: ['succinylcholine']

answer: @entity1170 :: (MESH:C564983,Disease) :: ['rapid sequence intubation']


abstract: @entity742 were fed diets containing 7.5% added @entity3106 , @entity3952 , or @entity21802 for 21 days. In addition, 50 microCi/kg cerium-141 was included for the last 10 days on experimental diets as an unabsorbed reference substance. In the rumen dietary @entity1674 were approximately 50% hydrolyzed, and hydrogenation resulted in saturation of the free @entity844 fraction. Some net synthesis of phospholipids, presumably microbial phospholipids, occurred in the rumen. In the intestine immediately distal to the pylorus, extensive secretion of @entity3645 , @entity165 , phospholipids, @entity1674 , free @entity1718 , and lipase occurred. This resulted in doubling of @entity844 fluxes through the duodenum. These endogenous secretions were reabsorbed rapidly however, with the major site of lipid and @entity6741 absorption in the region .6 to 4 m distal to the pylorus. Additional but less absorption occurred in the more distal segments of the small intestine. Overall absorption of @entity3106 , @entity3952 , and @entity21802 supplements was in the range 60 to 70%, and no differences were apparent between fats. @entity1474 were over 90% absorbed as compared with 55 to 65% for @entity1718 . No significant effect of any of the supplements was observed on ruminal total volatile @entity1718 , ratios of volatile @entity1718 , or on overall cellulose or caloric digestion.

title: Digestion and absorption of lipids and @entity3645 in @entity742 fed @entity3106 , @entity3952 , or XXXX .

entities_list: @entity21802 :: ('MESH:C022618', 'Chemical') :: ['tristearin']

entities_list: @entity3106 :: ('MESH:C031183', 'Chemical') :: ['stearic acid']

entities_list: @entity3952 :: ('MESH:D019301', 'Chemical') :: ['oleic acid']

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity1474 :: ('MESH:D005231', 'Chemical') :: ['Unsaturated fatty acids']

entities_list: @entity6741 :: ('CHEBI:3098', 'Chemical') :: ['bile acid']

entities_list: @entity3645 :: ('MESH:D001647', 'Chemical') :: ['bile acids']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids', 'saturated fatty acids']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity21802 :: (MESH:C022618,Chemical) :: ['tristearin']